You are not logged in. | Log in
In Progress
Clinical

ER+, age <45 and >70

Purpose

The aim of this study was to get a better understanding of the molecular and cellular influences of aging on breast cancer biology and clinical behaviour.

Hypothesis

The hypothesis of this study was that gene expression in breast cancer is age-specific and could explain age-related differences in breast cancer incidence and clinical behavior.

Experimental Design

Cryobanked breast cancer specimens excised from newly diagnosed Caucasian females were obtained from the National Cancer Institute – Bari (NCI-Bari) (n=71), following review board approval. Tumor specimen selection criteria included sporadic incidence (no first-degree relatives with breast cancer), >50% invasive cancer cellularity, a frozen wet weight of at least 100 mg, ER-positivity (>10% nuclear immunohistochemical stain), and patient age at diagnosis either ? 45 years (younger cases) or ? 70 years (older cases). The 71 NCI-Bari cases were all of ductal histology with mixed nodal status and without any outcome annotation. The two age cohorts in this tumor set showed no significant imbalances in the stage, the grade, and the PR status or ERBB2 status. PR-positivity was defined as ? 10% nuclear immunohistochemical staining, and ERBB2-positivity was defined as gene amplification.

Experimental Variables

--

Controls

--

Methods

The total RNA (3–5 ?g per sample) was labeled and analyzed using Affymetrix (Santa Clara, CA, USA) HT-HG_U133A Early Access Arrays with 22.9 K probes representing ~13 K unique UniGenes. Analyses were performed by standard Affymetrix procedures within the Lawrence Berkeley National Laboratory and Life Science Divison's Molecular Profiling Laboratory. Probe set measurements were generated from quantified Affymetrix image files (.CEL files) using the RMA algorithm in Bioconductor R. Array data were deposited in the public Gene Expression Omnibus database (GSE8193).

Gene expression values were mean centered, with a low variation filter applied to exclude probe sets that did not have at least 10 observations exhibiting a twofold change from the mean. Filtered probes were annotated (GeneTraffic annotation file, March 2006) and those with unknown UniGene symbols were omitted, yielding a final significant probe set of 6,632 annotated probes representing 5,109 unique genes. Unsupervised hierarchical clustering of the mean centered significant probe set was performed using Cluster (Eisen et al), and was visualized with Java TreeView (Saldanha et al). Phenotypes (for example, age cohort, PR status and ERBB2 status) of the resulting clusters were compared by chi-square test.

Additional Information

Yau, Christina, Vita Fedele, Ritu Roydasgupta, Jane Fridlyand, Alan Hubbard, Joe W. Gray, Karen Chew, et al. “Aging Impacts Transcriptomes but Not Genomes of Hormone-Dependent Breast Cancers.” Breast Cancer Research: BCR 9, no. 5 (2007): R59. doi:10.1186/bcr1765.

Eisen, M. B., P. T. Spellman, P. O. Brown, and D. Botstein. “Cluster Analysis and Display of Genome-Wide Expression Patterns.” Proceedings of the National Academy of Sciences of the United States of America 95, no. 25 (December 8, 1998): 14863–68.

Saldanha, Alok J. “Java Treeview--Extensible Visualization of Microarray Data.” Bioinformatics (Oxford, England) 20, no. 17 (November 22, 2004): 3246–48. doi:10.1093/bioinformatics/bth349.

PROBLEM MATCHING WITH OUR DATASET

Microarray
Affymetrix HG-U133A
47 Samples Loaded: 47
Human (Homo sapiens)
Nagalla 2013 , Breast Cancer Tissue
ER+ Breast Cancer
Sample Set Spreadsheet
Please log in in order to upload files.
Samples Preview
Sample ID series IMS IBS IDS ICR
GSM202716 NA NA NA NA NA
GSM202717 NA LumA IBD WID ICR2
GSM202718 NA NA NA NA NA
GSM202719 NA NA NA NA NA
GSM202720 NA NA NA NA NA
Please log in in order to upload files.
File
GSE8193_appended.meta.data_v1.csv
Sample Set Spreadsheet
Log2 Transformed
Raw Signal
  •   |  View in GXB »
Clinical Datasource
Links

Samples Viewer / Editor

All fields are editable except the "Sample ID" column. To edit a cell, click within the cell. To edit a "date" cell, click on the calendar icon. To cancel an edit, press the ESC key.

Sample ID Series IMS IBS IDS ICR Array Sample ID Sample Title DMFS 10Y EVENT DMFS 10Y TIME Disease Free Survival Event Disease Free Survival Distant Met Free Survival Event Distant Met Free Survival Age At Initial Pathologic Diagnosis Lymph Node Status ER Status PR Status Histology Differentiation Grade Tumor Size Cm Pathology T Stage
GSM202716
NA
NA
NA
NA
NA
400003242
breast tumor-b0307
NA
NA
NA
NA
NA
NA
76
LN-
ER+
PR+
NA
NA
NA
GSM202717
NA
LumA
IBD
WID
ICR2
400003243
breast tumor-b0335
DistantMetastasisFree
5.64
NA
NA
NA
NA
40
LN-
ER+
PR+
NA
NA
NA
GSM202718
NA
NA
NA
NA
NA
400003244
breast tumor-b0417
NA
NA
NA
NA
NA
NA
37
LN-
ER+
PR+
NA
NA
NA
GSM202719
NA
NA
NA
NA
NA
400003245
breast tumor-b0463
NA
NA
NA
NA
NA
NA
40
LN-
ER+
PR+
NA
NA
NA
GSM202720
NA
NA
NA
NA
NA
400003246
breast tumor-b0472
NA
NA
NA
NA
NA
NA
77
LN-
ER+
PR+
NA
NA
NA
GSM202721
NA
NA
NA
NA
NA
400003247
breast tumor-b0473
NA
NA
NA
NA
NA
NA
77
LN-
ER+
PR+
NA
NA
NA
GSM202722
NA
NA
NA
NA
NA
400003248
breast tumor - b0484
NA
NA
NA
NA
NA
NA
87
LN-
ER+
PR+
NA
NA
NA
GSM202723
NA
NA
NA
NA
NA
400003249
breast tumor - I005
NA
NA
NA
NA
NA
NA
37
LN+
ER+
PR+
NA
NA
NA
GSM202724
NA
NA
NA
NA
NA
400003250
breast tumor - I007
NA
NA
NA
NA
NA
NA
39
LN-
ER+
PR+
NA
NA
NA
GSM202725
NA
NA
NA
NA
NA
400003251
breast tumor - I019
NA
NA
NA
NA
NA
NA
44
LN+
ER+
PR+
NA
NA
NA
GSM202726
NA
NA
NA
NA
NA
400003252
breast tumor - I046
NA
NA
NA
NA
NA
NA
73
LN-
ER+
PR+
NA
NA
NA
GSM202727
NA
NA
NA
NA
NA
400003253
breast tumor - I050
NA
NA
NA
NA
NA
NA
39
LN+
ER+
PR-
NA
NA
NA
GSM202728
NA
NA
NA
NA
NA
400003254
breast tumor - I055
NA
NA
NA
NA
NA
NA
40
LN-
ER+
PR+
NA
NA
NA
GSM202729
NA
NA
NA
NA
NA
400003255
breast tumor - I083
NA
NA
NA
NA
NA
NA
31
LN+
ER+
PR+
NA
NA
NA
GSM202730
NA
NA
NA
NA
NA
400003256
breast tumor - I090
NA
NA
NA
NA
NA
NA
72
LN-
ER+
PR+
NA
NA
NA
GSM202731
NA
NA
NA
NA
NA
400003257
breast tumor - I097
NA
NA
NA
NA
NA
NA
83
Unknown
ER+
PR+
NA
NA
NA
GSM202732
NA
NA
NA
NA
NA
400003258
breast tumor - I099
NA
NA
NA
NA
NA
NA
79
Unknown
ER+
PR+
NA
NA
NA
GSM202733
NA
NA
NA
NA
NA
400003259
breast tumor - I101
NA
NA
NA
NA
NA
NA
80
Unknown
ER+
PR-
NA
NA
NA
GSM202734
NA
NA
NA
NA
NA
400003260
breast tumor - I108
NA
NA
NA
NA
NA
NA
37
LN+
ER+
PR+
NA
NA
NA
GSM202735
NA
NA
NA
NA
NA
400003261
breast tumor - I129
NA
NA
NA
NA
NA
NA
72
LN+
ER+
PR-
NA
NA
NA
GSM202736
NA
NA
NA
NA
NA
400003262
breast tumor - I130
NA
NA
NA
NA
NA
NA
41
LN-
ER+
PR+
NA
NA
NA
GSM202737
NA
NA
NA
NA
NA
400003263
breast tumor - I131
NA
NA
NA
NA
NA
NA
42
LN+
ER+
PR+
NA
NA
NA
GSM202738
NA
NA
NA
NA
NA
400003264
breast tumor - I139
NA
NA
NA
NA
NA
NA
41
LN-
ER+
PR-
NA
NA
NA
GSM202739
NA
NA
NA
NA
NA
400003265
breast tumor - I151
NA
NA
NA
NA
NA
NA
33
LN+
ER+
PR+
NA
NA
NA
GSM202740
NA
NA
NA
NA
NA
400003266
breast tumor - I153
NA
NA
NA
NA
NA
NA
78
LN+
ER+
PR+
NA
NA
NA
GSM202741
NA
NA
NA
NA
NA
400003267
breast tumor - I180
NA
NA
NA
NA
NA
NA
72
LN+
ER+
PR-
NA
NA
NA
GSM202742
NA
NA
NA
NA
NA
400003268
breast tumor - I189
NA
NA
NA
NA
NA
NA
73
LN+
ER+
PR-
NA
NA
NA
GSM202743
NA
NA
NA
NA
NA
400003269
breast tumor - I218
NA
NA
NA
NA
NA
NA
80
Unknown
ER+
PR-
NA
NA
NA
GSM202744
NA
NA
NA
NA
NA
400003270
breast tumor - I222
NA
NA
NA
NA
NA
NA
80
LN-
ER+
PR-
NA
NA
NA
GSM202745
NA
NA
NA
NA
NA
400003271
breast tumor - I227
NA
NA
NA
NA
NA
NA
71
LN+
ER+
PR+
NA
NA
NA
GSM202746
NA
NA
NA
NA
NA
400003272
breast tumor - I242
NA
NA
NA
NA
NA
NA
34
LN+
ER+
PR+
NA
NA
NA
GSM202747
NA
NA
NA
NA
NA
400003273
breast tumor - I261
NA
NA
NA
NA
NA
NA
45
LN+
ER+
PR+
NA
NA
NA
GSM202748
NA
NA
NA
NA
NA
400003274
breast tumor - I263
NA
NA
NA
NA
NA
NA
40
LN-
ER+
PR+
NA
NA
NA
GSM202749
NA
NA
NA
NA
NA
400003275
breast tumor - I272
NA
NA
NA
NA
NA
NA
74
LN+
ER+
PR+
NA
NA
NA
GSM202750
NA
NA
NA
NA
NA
400003276
breast tumor - I282
NA
NA
NA
NA
NA
NA
39
LN-
ER+
PR+
NA
NA
NA
GSM202751
NA
NA
NA
NA
NA
400003277
breast tumor - I289
NA
NA
NA
NA
NA
NA
74
LN-
ER+
PR+
NA
NA
NA
GSM202752
NA
NA
NA
NA
NA
400003278
breast tumor - I312
NA
NA
NA
NA
NA
NA
38
LN+
ER+
PR-
NA
NA
NA
GSM202753
NA
NA
NA
NA
NA
400003279
breast tumor - I317
NA
NA
NA
NA
NA
NA
80
LN+
ER+
PR-
NA
NA
NA
GSM202754
NA
NA
NA
NA
NA
400003280
breast tumor - I370
NA
NA
NA
NA
NA
NA
78
LN-
ER+
PR-
NA
NA
NA
GSM202755
NA
NA
NA
NA
NA
400003281
breast tumor - I427
NA
NA
NA
NA
NA
NA
45
LN+
ER+
PR+
NA
NA
NA
GSM202756
NA
NA
NA
NA
NA
400003282
breast tumor - I500
NA
NA
NA
NA
NA
NA
43
LN-
ER+
PR-
NA
NA
NA
GSM202757
NA
NA
NA
NA
NA
400003283
breast tumor - I503
NA
NA
NA
NA
NA
NA
72
LN+
ER+
PR-
NA
NA
NA
GSM202758
NA
NA
NA
NA
NA
400003284
breast tumor - s0166
NA
NA
NA
NA
NA
NA
70
LN-
ER+
PR+
NA
NA
NA
GSM202759
NA
NA
NA
NA
NA
400003285
breast tumor - s0372
NA
NA
NA
NA
NA
NA
44
LN-
ER+
PR+
NA
NA
NA
GSM202760
NA
NA
NA
NA
NA
400003286
breast tumor - s0395
NA
NA
NA
NA
NA
NA
41
LN-
ER+
PR-
NA
NA
NA
GSM202761
NA
NA
NA
NA
NA
400003287
breast tumor - s1748
NA
NA
NA
NA
NA
NA
40
LN-
ER+
PR+
NA
NA
NA
GSM202762
NA
NA
NA
NA
NA
400003288
breast tumor - s1777
NA
NA
NA
NA
NA
NA
76
LN-
ER+
PR+
NA
NA
NA

Group Sets View in Gene Expression Browser

Name  
All Samples Default  View
Immune Benefit Status   View
Immunological Constant of Rejection   View
Molecular Subtype   View
In order to make new Group Sets or change settings, please log in.

Module Analysis

Group Set  
All Samples
Immune Benefit Status
Immunological Constant of Rejection
Molecular Subtype
Your bug report has been sent!